Ser120
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser120  -  UBE2A (human)

Site Information
LDEPNPNsPANSQAA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448007

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 ) , phosphoamino acid analysis ( 3 ) , phosphopeptide mapping ( 3 )
Disease tissue studied:
luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 3 ) , HeLa (cervical) ( 2 )

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 3 ) , CDK2 (human) ( 3 )
Kinases, in vitro:
CDK1 (human) ( 3 ) , CDK2 (human) ( 3 )
Treatments:
nocodazole ( 3 ) , seliciclib ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Sarcevic B, Mawson A, Baker RT, Sutherland RL (2002) Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J 21, 2009-18
11953320   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.